This comes from a stockmarket earnings preview newsletter from Jan 26th. Firstly good to see where Heartware sits against Thoratec with the analysts ratings but what l really like is the earnings forecast of $107.4 mill for this quarter. These numbers imo will be exceeded by HIN within a year of FDA approval.
"Thoratec (Nasdaq: THOR ) will try to beat its earnings estimates for the third consecutive quarter. The company will unveil its latest earnings on Monday, Jan. 30. Thoratec Laboratories develops, manufactures and markets proprietary medical devices used for circulatory support.
What analysts say:
Buy, sell, or hold?: Analysts think investors should stand pat on Thoratec with 10 of 17 analysts rating it hold. Analysts don't like Thoratec as much as competitor Heartware, International overall. Six out of 11 analysts rate Heartware, International a buy compared to seven of 17 for Thoratec. Revenue Forecasts: On average, analysts predict $107.4 million in revenue this quarter. That would represent a rise of 10.1% from the year-ago quarter."
HIN Price at posting:
$1.80 Sentiment: Buy Disclosure: Held
